PLEASANTON, Calif.--(BUSINESS WIRE)--10x Genomics, Inc., today announced the signing of a co-marketing agreement with Illumina, Inc., for the promotion and sales of 10x's Linked-Read sequencing products and Illumina sequencing systems to address long-range genomics applications.
"Illumina is the undisputed market leader in DNA sequencing, providing high-throughput, high accuracy, and low cost sequencing solutions," said Dr. Serge Saxonov, 10x's Chief Executive Officer. "Pairing the power of Linked-Reads with the power of Illumina sequencing will redefine the way we look at and understand genetic information."
10x's microfluidics-based molecular barcoding solutions, built on the proprietary GemCode™ technology, enable researchers to pursue powerful new sequencing applications with their Illumina sequencers. This includes phasing, structural variant analysis, de novo genome assembly, and remapping of difficult regions of the genome. The Companies will each be co-marketing the 10x GemCode technology and Illumina sequencing solutions to their respective customers. The Illumina relationship, along with 10x's other partnerships in sample prep, genome and exome sequencing, and single cell analysis, provides customers with powerful new 'sample to answer' workflows to address a wide range of their analysis needs.
"The GemCode technology provides HiSeq XTM Ten, HiSeq®, NextSeq® and Miseq® sequencing users a plug-and-play upgrade to their existing systems, giving them access to a broad range of critical information, and at a much lower cost and a higher quality than other long-read sequencing systems on the market," said Christian Henry, Executive Vice President and Chief Commercial Officer, Illumina. "Our customers will benefit from the new possibilities enabled by our combined technologies."
About 10x Genomics, Inc.
10x Genomics meets the critical need for long range, structural and cellular information, with an innovative system that transforms the capability of existing short-read sequencers. Our Chromium™ System supports comprehensive genomics and high-throughput single cell transcriptomics. It enables researchers to discover previously inaccessible genomic information at unprecedented scale, including phased structural variants, phased single nucleotide variants, and dynamic gene expression of individual cells—while leveraging their existing sequencing systems and workflows.